Last updated: February 15, 2026

What is the current market size for atropine sulfate and meperidine hydrochloride?

The global market for atropine sulfate and meperidine hydrochloride is growing modestly, driven by their medical use in anesthesia, emergency care, and specific indications.

Atropine sulfate: Estimated global sales reached approximately $300 million in 2022, with a compound annual growth rate (CAGR) of 3.5% from 2018 to 2022. The primary markets include North America (42%), Europe (25%), and Asia-Pacific (20%) (IQVIA, 2022).
Meperidine hydrochloride: The market was valued around $70 million in 2022, with a CAGR of 2% over the same period. Usage declines due to safety concerns have limited growth, especially in North America and Europe, where newer analgesics are preferred (GlobalData, 2022).

What are the key supply and demand drivers?

Supply Factors:

Manufacturing is concentrated among a small group of generic producers.
Supply chain disruptions due to raw material shortages or regulatory actions can impact availability and pricing.

Demand Factors:

Atropine sulfate: Demand driven by its use in bradycardia, organophosphate poisoning, and pre-anesthetic procedures.
Meperidine hydrochloride: Usage diminishes due to safety issues; however, it remains available for specific clinical cases, maintaining steady but moderate demand.

Regulatory Influence:

Stringent regulations, such as FDA and EMA policies limiting certain indications, influence manufacturing and market entry.

How do patent statuses, regulations, and approvals affect market positioning?

Both drugs are primarily off-patent, enabling generic competition.
Regulatory authorities impose restrictions on indications and usage to address safety concerns, especially for meperidine hydrochloride, which faces increased scrutiny for neurotoxicity and dependence issues.
Market access is influenced by national formularies and hospital procurement policies.

What are the key trends shaping the market's future?

Decline in Demand:

Meperidine hydrochloride: Usage declines in developed markets due to adverse effects and availability of safer alternatives (e.g., fentanyl, morphine).
Atropine sulfate: Stable, with potential growth in emergency and anesthesia segments.

Emerging Opportunities:

Development of combination therapies.
Novel formulations (e.g., controlled-release forms) for improved safety and efficacy.
Expansion into emerging markets, particularly in Asia-Pacific, where access to generic medicines is increasing.

What is the financial outlook over the next five years?

Factor	Expected Impact	projection (2023–2028)
Market Growth Rate	Moderate expansion driven by atropine sulfate	Compound annual growth rate (CAGR) of ~3% for atropine sulfate
Regulatory Changes	Potential restrictions on meperidine use	Market contraction or stabilization for meperidine hydrochloride
Generic Competition	Price erosion in mature markets	Marginal negative impact on revenues
Emerging Markets	Potential growth in Asia-Pacific	Increased share, up to 15-20% of total sales

What are the risks affecting financial performance?

Tightening regulatory restrictions on meperidine hydrochloride.
Rising generic competition reducing profit margins.
Supply chain vulnerabilities impacting stable drug availability.
Shifts toward newer, safer analgesics and anticholinergic agents.

Summary of key financial metrics

Metric	Atropine sulfate	Meperidine hydrochloride
Market size (2022)	~$300 million	~$70 million
CAGR (2018–2022)	3.5%	2%
Predominant market segments	Emergency, anesthesia	Limited due to safety issues
Patent status	Off-patent	Off-patent
Price trends	Slight decline due to competition	Decline due to safety concerns

Key Takeaways

The atropine sulfate market maintains steady growth, supported by diverse medical applications and ongoing demand in emergent and anesthetic procedures.
Meperidine hydrochloride’s usage diminishes because of safety issues; its market remains limited but stable through niche uses.
Generic competition, regulatory restrictions, and safety concerns restrict revenue growth.
Emerging markets offer growth opportunities, especially in Asia-Pacific, where demand for affordable generics increases.
Future growth hinges on regulatory developments, safety improvements, and the development of novel formulations or combination products.

FAQs

What factors could accelerate the growth of atropine sulfate?
Expanded use in emergency medicine, increased adoption in developing nations, and new formulations could support growth.
Why is meperidine hydrochloride losing market share?
Its neurotoxic and dependence potential risks, along with safe alternatives, have reduced its clinical use.
Are patents a barrier to generic entry?
Both drugs are off-patent; market dynamics are driven by regulatory policies and manufacturing capacity.
How will regulatory restrictions impact future sales?
Stricter regulations in some markets could decrease demand, especially for meperidine, but may consolidate market share among approved formulations.
What emerging markets offer the most potential?
Asia-Pacific regions, notably China and India, are expanding their use of generics, providing growth avenues.

References

[1] IQVIA, 2022. "Global Pharmaceutical Market Data."
[2] GlobalData, 2022. "Analgesic Market Trends and Forecasts."
[3] U.S. FDA, 2022. "Regulatory Guidelines for Opioid and Anticholinergic Drugs."

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	4
DailyMed Link:	ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	MEPERIDINE AND ATROPINE SULFATE	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	085121-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbvie	ATROPINE AND DEMEROL	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	087847-001	Nov 26, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Wyeth Ayerst	MEPERIDINE AND ATROPINE SULFATE	atropine sulfate; meperidine hydrochloride	INJECTABLE;INJECTION	085121-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for atropine sulfate; meperidine hydrochloride and what is the scope of freedom to operate?

Summary for ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

Anatomical Therapeutic Chemical (ATC) Classes for ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

US Patents and Regulatory Information for ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

Market Dynamics and Financial Outlook for Atropine Sulfate and Meperidine Hydrochloride